Glögl M., Friedrich N., Cerutti G. et al. (2023). Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization. Nat Struct Mol Biol. doi.org/10.1038/s41594-023-01062-z

Feraoun Y, Palgen JL, Joly C, Tchitchek N, Marcos-Lopez E, Dereuddre-Bosquet N, et al. (2022). The route of Vaccine Administration determines whether blood neutrophils undergo long-term phenotypic modifications. Frontiers in Immunology. 2022;12. doi.org/10.3389/fimmu.2021.784813.

Malatinkova E, Thomas J, De Spiegelaere W, Rutsaert S, Geretti AM, Pollakis G, et al. (2021). Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising Human Alu Repeat Sequences. Life. 2021; 11(12):1410. doi.org/10.3390/life11121410.

Highton AJ, Diercks B-P, Möckl F, Martrus G, Sauter J, Schmidt AH, et al. (2020). High metabolic function and resilience of NKG2A-educated NK Cells. Frontiers in Immunology. 2020;11. doi.org/10.3389/fimmu.2020.559576.

Hauser A, Carnell G, Held K, Sulbaran G, Tischbierek N, Rogers L, et al. (2021). Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. Vaccines. 2021; 9(7):750. doi.org/10.3390/vaccines9070750.

Friedrich N, Stiegeler E, Glögl M, Lemmin T, Hansen S, Kadelka C, et al. (2021). Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization. Nat Commun 12, 6705. doi.org/10.1038/s41467-021-27075-0.

Lungu C, Banga R, Gruters R, & Procopio AF. (2021). Inducible HIV-1 Reservoir Quantification: Clinical Relevance, Applications and Advancements of TILDA. Front. Microbiol. 2021 Jun 15. doi.org/10.3389/fmicb.2021.6866900.

Peterhoff D, Thalhauser S, Sobczak JM, Mohsen MO, Voigt C, Seifert N, et al. (2021). Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery. Vaccines, 9(6):642. 2021 Jun 11. doi.org/10.3390/vaccines9060642.

Rao S, Lungu C, Crespo R, Steijaert TH, Gorska A, Palstra, RJ, et al. (2021). Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir. Nature communications12(1), 2475. 2021 Apr 30. doi.org/10.1038/s41467-021-22608-z.

Lungu C, Procopio FA, Overmars RJ, Beerkens R, Voermans J, Rao S, et al. (2020). Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA. Viruses, 12(9), 973. 2020 Sep 02doi.org/10.3390/v12090973.

Joachim A, Ahmed M, Pollakis G, Rogers L, Hoffmann VS, Munseri P, et al. (2020). Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost. Frontiers in immunology11, 719. 2020 Apr 28. doi.org/10.3389/fimmu.2020.00719.

Palgen JL, Tchitchek N, Rodriguez-Pozo A, Jouhault Q, Abdelhouahab, Dereuddre-Bosquet N, et al. (2020). Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations. npj Vaccines 5, 24. doi.org/10.1038/s41541-020-0175-8.

Su B, Dispinseri S, Iannone V, Zhang T, Wu H, Carapito R, et al. (2019). Update on FC-mediated antibody functions against HIV-1 beyond neutralization. Frontiers in Immunology. 2019;10. doi.org/10.3389/fimmu.2019.02968.

Couto E, Diaz-Brito V, Mothe B, Guardo AC, Fernandez I, Ugarte A, et al. (2019). Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B. Vaccines. 2019; 7(4):178. doi.org/10.3390/vaccines7040178.

Wilmschen S, Schmitz JE, Kimpel J. (2019). Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV. Vaccines. 2019; 7(3):119. doi.org/10.3390/vaccines7030119.

Bresk CA, Hofer T, Wilmschen S, Krismer M, Beierfuß A, Effantin G, et al. (2019). Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. Viruses. 2019; 11(2):159. doi.org/10.3390/v11020159.

Perdiguero B, Gómez CE, García-Arriaza J, Sánchez-Corzo C, Sorzano CÓS, Wilmschen S, et al. (2019). Heterologous combination of VSV-gp and NYVAC vectors expressing HIV-1 trimeric GP145 env as vaccination strategy to induce balanced B and T cell immune responses. Frontiers in Immunology. 2019;10. doi.org/10.3389/fimmu.2019.02941.

Pérez P, Marín MQ, Lázaro-Frías A, Sorzano CÓS, Di Pilato M, Gómez CE, Esteban M, García-Arriaza J. (2019). An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design. Vaccines. 2019; 7(4):208. doi.org/10.3390/vaccines7040208.

Perdiguero B, Sánchez-Corzo C, Sorzano COS, Saiz L, Mediavilla P, Esteban M, Gómez CE. (2019). A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses. Viruses. 2019; 11(2):160. doi.org/10.3390/v11020160.

Raman SC, Mejias-Pérez E, Gomez CE, García-Arriaza J, Perdiguero B, Vijayan A, et al. (2019). The envelope-based fusion antigen gp120c14k forming hexamer-like structures triggers T cell and neutralizing antibody responses against HIV-1. Frontiers in Immunology, 10. doi.org/10.3389/fimmu.2019.02793.

Wittner M, Schlicker V, Libera J, Bockmann JH, Horvatits T, Seiz O, et al. (2019) Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis. PLOS ONE 14(7): e0220008. doi.org/10.1371/journal.pone.0220008.

Moore C, Stöhr W, Crook AM, Richert L, Leliévre JD, Pantaleo G, et al. (2019). Multi-arm multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV, 6(5):e334-e340. 2019 May 01. doi.org/10.1016/S2352-3018(19)30082-7.

Nadai Y, Held K, Joseph S, Ahmed M, Hoffmann VS, Peterhoff D, et al. (2019). Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence. Frontiers in immunology10, 717. 2019 Apr 24. doi.org/10.3389/fimmu.2019.00717.

Jean-Louis P, Tchitchek N, Huot N, Elhmouzi-Younes J, Lefebvre C, Rosenbaum P, et al. (2019). NK cell immune responses differ after prime and boost vaccination. Journal of Leukocyte Biology, Volume 105, Issue 5, May 2019, Pages 1055–1073. doi.org/10.1002/JLB.4A1018-391RR.

Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, et al. (2018). Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. PLoS ONE 13(12): e0208345. doi.org/10.1371/journal.pone.0208345.

Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, et al. (2018). Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine. Human Gene Therapy.Sep 2018.1011-1028. doi.org/10.1089/hum.2018.075.

Pfeifer C, Highton AJ, Peine S, Sauter J, Schmidt AH, Bunders MJ, et al. (2018). Natural killer cell education is associated with a distinct glycolytic profile. Frontiers in Immunology. 2018;9. doi.org/10.3389/fimmu.2018.03020.

Wagner R, Asbach B. (2018). Dürfen wir noch auf eine HIV-Impfung hoffen? MMW - Fortschritte der Medizin 160 (Suppl 2), 24–27. doi.org/10.1007/s15006-018-0649-z.

Palgen JL, Tchitchek N, Elhmouzi-Younes J, Delandre S, Namet I, Rosenbaum P, et al. (2018). Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response. Sci Rep 8, 3087. doi.org/10.1038/s41598-018-21222-2.

Parsons MS, Le Grand R, Kent SJ. (2018). Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Viruses. 2018; 10(6):333. doi.org/10.3390/v10060333.

Kratochvil S, McKay PF, Chung AW, Kent SJ, Gilmour J, Shattock RJ. Immunoglobulin G1 allotype influences antibody subclass distribution in response to HIV GP140 vaccination. Frontiers in Immunology. 2017;8. doi.org/10.3389/fimmu.2017.01883.

Leal L, Lucero C, Gatell JM, Gallart T, Plana M, García F. (2017). New challenges in therapeutic vaccines against HIV infection. Expert Review of Vaccines, 16:6, 587-600. doi.org/10.1080/14760584.2017.1322513.

Mayr LM, Su B, Moog C. (2017). Non-neutralizing antibodies directed against HIV and their functions. Frontiers in Immunology. 2017;8. doi.org/10.3389/fimmu.2017.01590.

Kratochvil S, McKay PF, Kopycinski JT, Bishop C, Hayes PJ, Muir L, et al. (2017). A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Frontiers in immunology8, 595. 2017 May 24. doi.org/10.3389/fimmu.2017.00595/fimmu.2017.00595

Peterhoff D, Wagner R. (2017). Guiding the long way to broad HIV neutralization. Current Opinion in HIV and AIDS, 12(3):p 257-264, May 2017. doi.org/10.1097/COH.0000000000000356.

Wagner R. (2017). Effective HIV vaccine: narrow path to broadly neutralizing antibodies? Current Opinion in HIV and AIDS, 12(3):p 191-194, May 2017. doi.org/10.1097/COH.0000000000000371.

Asbach B, Wagner R. (2017). Particle-based delivery of the HIV envelope protein. Current Opinion in HIV and AIDS, 12(3):p 265-271, May 2017. doi.org/10.1097/COH.0000000000000366.

Medina-Ramírez M, Sanders RW, Sattentau QJ. (2017). Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Current Opinion in HIV and AIDS, 12(3):p 241-249, May 2017. doi.org/10.1097/COH.0000000000000363.

News

  • EHVA P01: a phase I, prophylactic HIV vaccine trial

    EHVA P01 / ANRS VRI08 is a phase I, prophylactic HIV vaccine trial to evaluate the safety and...

    Read More …

  • EHVA Latest News

    EHVA latest newsletter is available...

    Read More …

  • EHVA Halts Phase II EHVA-T02 Clinical Trial of a Candidate Therapeutic HIV Vaccine and Immunotherapy Drug

    The European HIV Vaccine Alliance (EHVA) has announced that the EHVA T02 / ANRS VRI07 trial, a...

    Read More …

europa  

This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032